转化医学

订阅

MedSci主页 / 所有栏目 / 转化医学

抗癌免疫疗法新药获成功

2016-09-12 佚名 生物谷

免疫疗法
关注

（图片摘自www.sciencealert.com）科学家们最近研究出了一种能够有效杀伤恶性胰腺癌的药物，而且没有伴随明显的副作用。 该药物叫做“IMM-101”，它能够唤醒体内的免疫系统从而对肿瘤进行杀伤。由于胰腺癌自然状态下会主动逃避体内免疫系统的识别，因此该药物的出现对于该类肿瘤的治疗具有重大的意义。 来自英国伦敦大学的研究者们通过将IMM-101与已有的化疗药物gemcitab


（图片摘自www.sciencealert.com）

科学家们最近研究出了一种能够有效杀伤恶性胰腺癌的药物，而且没有伴随明显的副作用。

该药物叫做“IMM-101”，它能够唤醒体内的免疫系统从而对肿瘤进行杀伤。由于胰腺癌自然状态下会主动逃避体内免疫系统的识别，因此该药物的出现对于该类肿瘤的治疗具有重大的意义。

来自英国伦敦大学的研究者们通过将IMM-101与已有的化疗药物gemcitabine进行联合使用，发现其能够有效杀伤胰腺癌细胞外周的保护性细胞，以及能够延长转移胰腺癌患者的寿命。

“这对我来说是十分兴奋的”，首席研究者Angus Dalgleish说道。“这是我们首次找到能够帮助控制胰腺癌的免疫疗法”。

接受该免疫治疗药物的患者均表示相比传统化学疗法要舒服一些。而且研究结果表明该疗法没有明显的副作用。

虽然早期的研究结果十分喜人，但这并不能说明该药物具有治愈胰腺癌的能力。而且，由于该实验仅仅囊括了110名患者，因此还需要提高样本数量来获得更加可靠的结果。

Dalgleish对于IMM-101的研究已经有很长的时间，此前也有结果表明其对皮肤癌以及肺癌有一定的治疗效果，但鉴于胰腺癌的难治现象由来已久，最近的这项研究结更加有意义。

目前研究者们计划进行下一步更大规模的研究，从而完全验证此前得到的结果。

目前晚期胰腺癌患者的寿命极短，不超过18%的患者能够坚持一年以上，而转移性的胰腺癌患者寿命更加有限。根据调查， 全球范围内的胰腺癌患者寿命仅有2.7-5.8个月。

希望IMM-101的出现能够帮助缓解这一窘境。

相关结果发表在《British Journal of Cancer》杂志上。

原始出处

Experimental drug fights cancer by 'waking up' the immune system

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=126278, encodeId=2da21262e843, content=学习了，赞一个！！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Wed Sep 14 09:51:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126271, encodeId=98a31262e12e, content=学习了，赞一个！！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Wed Sep 14 09:48:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126114, encodeId=75c2126114ec, content=学习了，赞一个！！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Wed Sep 14 08:26:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=125119, encodeId=960312511941, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 13 12:12:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=125118, encodeId=7458125118d2, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 13 12:11:00 CST 2016, time=2016-09-13, status=1, ipAttribution=)]
    2016-09-14 1dd8a7c5m95(暂无匿称)

    学习了，赞一个！！！

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=126278, encodeId=2da21262e843, content=学习了，赞一个！！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Wed Sep 14 09:51:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126271, encodeId=98a31262e12e, content=学习了，赞一个！！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Wed Sep 14 09:48:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126114, encodeId=75c2126114ec, content=学习了，赞一个！！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Wed Sep 14 08:26:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=125119, encodeId=960312511941, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 13 12:12:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=125118, encodeId=7458125118d2, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 13 12:11:00 CST 2016, time=2016-09-13, status=1, ipAttribution=)]
    2016-09-14 1dd8a7c5m95(暂无匿称)

    学习了，赞一个！！！

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=126278, encodeId=2da21262e843, content=学习了，赞一个！！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Wed Sep 14 09:51:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126271, encodeId=98a31262e12e, content=学习了，赞一个！！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Wed Sep 14 09:48:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126114, encodeId=75c2126114ec, content=学习了，赞一个！！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Wed Sep 14 08:26:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=125119, encodeId=960312511941, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 13 12:12:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=125118, encodeId=7458125118d2, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 13 12:11:00 CST 2016, time=2016-09-13, status=1, ipAttribution=)]
    2016-09-14 1dd8a7c5m95(暂无匿称)

    学习了，赞一个！！！

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=126278, encodeId=2da21262e843, content=学习了，赞一个！！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Wed Sep 14 09:51:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126271, encodeId=98a31262e12e, content=学习了，赞一个！！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Wed Sep 14 09:48:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126114, encodeId=75c2126114ec, content=学习了，赞一个！！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Wed Sep 14 08:26:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=125119, encodeId=960312511941, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 13 12:12:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=125118, encodeId=7458125118d2, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 13 12:11:00 CST 2016, time=2016-09-13, status=1, ipAttribution=)]
    2016-09-13 doctorJiangchao

    继续关注

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=126278, encodeId=2da21262e843, content=学习了，赞一个！！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Wed Sep 14 09:51:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126271, encodeId=98a31262e12e, content=学习了，赞一个！！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Wed Sep 14 09:48:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126114, encodeId=75c2126114ec, content=学习了，赞一个！！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Wed Sep 14 08:26:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=125119, encodeId=960312511941, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 13 12:12:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=125118, encodeId=7458125118d2, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 13 12:11:00 CST 2016, time=2016-09-13, status=1, ipAttribution=)]
    2016-09-13 doctorJiangchao

    继续学习

    0

相关资讯

JCO：非小细胞肺癌的免疫疗法vs肿瘤疫苗的效果

细胞程序性死亡蛋白-1检查点抑制剂近期被批准用于晚期非小细胞肺癌(NSCLC)的二线治疗。不幸是事，只有一个亚组的人群对治疗有反应，获得了长期生存。肿瘤疫苗和细胞免疫治疗可与检查点抑制剂产生协同作用，但哪种治疗最有效尚不清楚。在这个meta分析中，我们评估了肿瘤疫苗和细胞免疫疗法对NSCLC的有效性。 搜索了关于NSCLC治疗的细胞免疫疗法或肿瘤疫苗的随机对照研究 (RCTs) 。使用随机效

施贵宝Opdivo PK 默沙东Keytruda，肺癌市场谁胜出？

抗肿瘤免疫疗法当下最大的赢家无疑是免疫哨卡抑制剂，其中最耀眼的产品当属施贵宝的Opdivo和默沙东的Keytruda。虽然Keytruda通过一个超大型一期临床试验得以成功“弯道超车”，提前3个月在美国上市，成为FDA批准的首个PD-1抑制剂。但施贵宝稳扎稳打，在美国市场起步落后的情况下，2015年依然以21亿美元的销售额遥遥领先Keytruda（21 亿美元相比5.66亿美元），而且今年

JCO：控制晚期癌症患者的免疫系统有助于提高其生活质量

来自爱丁堡大学的一项新的研究表明，控制晚期癌症患者的免疫系统有助于提高其生活质量，该研究结果已发表于Journal of Clinical Oncology。研究共纳入了2520名欧洲癌症患者，评估其炎症水平，发现炎症水平直接影响到患者对疼痛、疲劳、食欲和恶心等方面的感受。该研究所纳入的参与者最常见的癌症类型的胃肠道（585名；22.2%）和肺（443名；17.6%）部肿瘤，中位生存期为4.25个

大牛Nature全新综述：为免疫疗法“挑大梁”，4大方向让CAR-T更“聪明”！

8月23日，这一题为“Engineered T cells: the promise and challenges of cancer immunotherapy”的综述在线发表于Nature Reviews Cancer杂志上。宾夕法尼亚大学佩雷尔曼医学院的Andrew D. Fesnak博士和Bruce L. Levine教授是这篇文章的共同通讯作者，Carl H. June教授是本文的共

走入临床的RNA分子

在以往RNA的研究中，主要注重其结构和功能的研究，近日，来自美国杜克大学医学中心的学者Sullenger在Science杂志上发文，总结了当前RNA在临床应用中的进展，就RNA的临床运用情况为广大科研和医疗工作者做了详细的介绍。根据RNA参不参与蛋白质编码，分为编码RNA（mRNA）和非编码RNA（siRNA、miRNA、RNA适体、gRNA）。不同类型的RNA根据其作用机制不同在临床疾病中的应用

Nature综述：癌症免疫疗法是“牛”，那安全性呢？

近几年，免疫疗法飞速发展，给癌症患者带来了前所未有的希望。其中，免疫检查点抑制剂已经获批用于治疗多种癌症类型。然而，这些新型疗法其实也带来了一些独特的不良反应。近期，Nature子刊上发表的一篇综述聚焦了这些毒性作用。作者们希望能够为新疗法的应用提供一些指导。